Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working group.

Takimoto CH, Remick SC, Sharma S, Mani S, Ramanathan RK, Doroshow JH, Hamilton A, Mulkerin D, Graham M, Lockwood GF, Ivy P, Egorin M, Greenslade D, Goetz A, Grem JL.

Semin Oncol. 2003 Aug;30(4 Suppl 15):20-5.

PMID:
14523791
2.

Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study.

Takimoto CH, Remick SC, Sharma S, Mani S, Ramanathan RK, Doroshow J, Hamilton A, Mulkerin D, Graham M, Lockwood GF, Ivy P, Egorin M, Schuler B, Greenslade D, Goetz A, Knight R, Thomas R, Monahan BP, Dahut W, Grem JL; National Cancer Institute Organ Dysfunction Working Group Study.

J Clin Oncol. 2003 Jul 15;21(14):2664-72.

PMID:
12860942
3.

In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration.

Lin YS, Lockwood GF, Graham MA, Brian WR, Loi CM, Dobrinska MR, Shen DD, Watkins PB, Wilkinson GR, Kharasch ED, Thummel KE.

Pharmacogenetics. 2001 Dec;11(9):781-91.

PMID:
11740342
4.

Phase I pharmacokinetic study of the novel antitumor agent SR233377.

LoRusso PM, Foster BJ, Wozniak A, Heilbrun LK, McCormick JI, Ruble PE, Graham MA, Purvis J, Rake J, Drozd M, Lockwood GF, Corbett TH.

Clin Cancer Res. 2000 Aug;6(8):3088-94.

5.

Clinical pharmacokinetics of oxaliplatin: a critical review.

Graham MA, Lockwood GF, Greenslade D, Brienza S, Bayssas M, Gamelin E.

Clin Cancer Res. 2000 Apr;6(4):1205-18. Review.

6.

Characterization of the highly variable bioavailability of tiludronate in normal volunteers using population pharmacokinetic methodologies.

Maier GA, Lockwood GF, Oppermann JA, Wei G, Bauer P, Fedler-Kelly J, Grasela T.

Eur J Drug Metab Pharmacokinet. 1999 Jul-Sep;24(3):249-54.

PMID:
10716064
7.

Dose regimen adjustment for milrinone in congestive heart failure patients with moderate and severe renal failure.

Woolfrey SG, Hegbrant J, Thysell H, Fox PA, Lendrem DW, Lockwood GF, Lasher K, Rogers J, Greenslade D.

J Pharm Pharmacol. 1995 Aug;47(8):651-5.

PMID:
8583366
8.

In vitro drug metabolism and pharmacokinetics of diazepam in cynomolgus monkey hepatocytes during culture for six days.

Seddon T, Lockwood GF, Chenery RJ.

Biochem Pharmacol. 1989 Aug 15;38(16):2621-30.

PMID:
2504170
9.

Mean residence time for drugs subject to enterohepatic cycling.

Shepard TA, Lockwood GF, Aarons LJ, Abrahams ID.

J Pharmacokinet Biopharm. 1989 Jun;17(3):327-45.

PMID:
2810071
10.

The antipyrine breath test in the rat: a pharmacokinetic model.

Lockwood GF, Chenery RJ, Oldham HG, Standring P, Norman SJ.

Eur J Drug Metab Pharmacokinet. 1988 Jul-Sep;13(3):207-14.

PMID:
3149242
11.

Pharmacokinetics of flurbiprofen in man. I. Area/dose relationships.

Szpunar GJ, Albert KS, Bole GG, Dreyfus JN, Lockwood GF, Wagner JG.

Biopharm Drug Dispos. 1987 May-Jun;8(3):273-83.

PMID:
3593904
12.

Accumulation and time to steady state for drugs subject to enterohepatic cycling: a stimulation study.

Shepard TA, Gannaway DJ, Lockwood GF.

J Pharm Sci. 1985 Dec;74(12):1331-3.

PMID:
4087202
13.

Pharmacokinetics of ibuprofen in man IV: absorption and disposition.

Wagner JG, Albert KS, Szpunar GJ, Lockwood GF.

J Pharmacokinet Biopharm. 1984 Aug;12(4):381-99.

14.

Effects of age on the clinical pharmacokinetics of ibuprofen.

Albert KS, Gillespie WR, Wagner JG, Pau A, Lockwood GF.

Am J Med. 1984 Jul 13;77(1A):47-50.

PMID:
6380280
15.

Campylobacter septic abortion.

Jost PM, Galvin MC, Brewer JH, Lockwood GF.

South Med J. 1984 Jul;77(7):924.

PMID:
6740362
16.

Comparative bioavailability study of two tablet formulations of cimetidine.

Berardi RR, Cohen IA, Hyneck ML, Lockwood GF, Shukla UA, Sakmar E, Wells JJ, Wagner JG.

Biopharm Drug Dispos. 1984 Apr-Jun;5(2):169-76.

PMID:
6743784
17.

Pharmacokinetics of ibuprofen in man--III: Plasma protein binding.

Lockwood GF, Albert KS, Szpunar GJ, Wagner JG.

J Pharmacokinet Biopharm. 1983 Oct;11(5):469-82.

18.

Estimation of number of receptor sites, binding capacity or Vm.

Lockwood GF, Wagner JG.

Biopharm Drug Dispos. 1983 Oct-Dec;4(4):397-9. No abstract available.

PMID:
6661517
19.

Pharmacokinetics of ibuprofen in man. I. Free and total area/dose relationships.

Lockwood GF, Albert KS, Gillespie WR, Bole GG, Harkcom TM, Szpunar GJ, Wagner JG.

Clin Pharmacol Ther. 1983 Jul;34(1):97-103.

20.

Plasma volume changes as a result of equilibrium dialysis.

Lockwood GF, Wagner JG.

J Pharm Pharmacol. 1983 Jun;35(6):387-8. No abstract available.

PMID:
6135780
21.

Determination of myocardial and serum digoxin concentrations in children by specific and nonspecific assay methods.

Wagner JG, Dick M 2nd, Behrendt DM, Lockwood GF, Sakmar E, Hees P.

Clin Pharmacol Ther. 1983 May;33(5):577-84.

22.
23.
24.

Influence of phenobarbitone pretreatment on disposition of amidopyrine and its metabolites in rat.

Lockwood GF, Houston JB.

J Pharm Pharmacol. 1980 Sep;32(9):619-23.

PMID:
6107362
25.

Amidopyrine disposition in rat.

Lockwood GF, Houston JB.

J Pharm Pharmacol. 1979 Nov;31(11):787-8. No abstract available.

PMID:
41916
26.

Aminopyrine demethylation kinetics: comparison of plasma and exhaled metabolites [proceedings].

Houston JB, Lockwood GF.

Br J Pharmacol. 1979 Jul;66(3):429P. No abstract available.

27.

Estriol determinations in insulin-dependent diabetes in pregnancy.

Lockwood GF, Newman RL.

Mo Med. 1976 Aug;73(8):469-72. No abstract available.

PMID:
958182
28.

Estriol determinations in gestational diabetes.

Lockwood GF, Newman RL.

Obstet Gynecol. 1974 Nov;44(5):642-5. No abstract available.

PMID:
4608396
29.

Estriol determination in random urine samples.

Lockwood GF, Newman RL.

Obstet Gynecol. 1974 Mar;43(3):343-6. No abstract available.

PMID:
4814451
30.

The possibel role of uric acid in the ecology of Histoplasma capsulatum.

Lockwood GF, Garrison RG.

Mycopathol Mycol Appl. 1968 Oct 14;35(3):377-88. No abstract available.

PMID:
5696730

Supplemental Content

Loading ...
Support Center